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Abstract
Objective: To analyze the association between neutrophil-to-lymphocyte ratio (NLR)
and intravesical prostatic protrusion (IPP) in men with benign prostatic hyperplasia.
Methods: Two hundred and fifty men aged >50 years who presented with lower uri-
nary tract symptoms at our institution between 2014 and 2018 were analyzed.
Pearson's method was used for analysis of the correlation between NLR and IPP.
Multivariate logistic regression analysis was used to identify predictors of IPP. Fur-
ther analysis according to total prostate volume (TPV) was performed.
Results: The NLR correlated positively with IPP (Pearson's r = 0.459, P < 0.001) and
was an independent predictor of IPP ≥10 mm (odds ratio, 2.95; 95% confidence
interval, 1.59–5.47; P = 0.0006). Among the 142 men with prostates <40 cm3, mean
NLR was 2.50 ± 0.71 in those with IPP ≥10 mm and 1.71 ± 0.57 in those with
IPP < 10 mm (P < 0.001). The NLR differed significantly between those with a pros-
tate <40 cm3 and IPP ≥10 mm and those with a larger prostate and IPP < 10 mm
(2.50 ± 0.71 vs 2.07 ± 0.77, respectively; P = 0.020).
Conclusions: NLR can be used as a surrogate marker for presence of IPP. Its clinical
value would be especially important in men with a small prostate gland but high IPP.
The NLR seemed to be more strongly correlated with IPP than with TPV.
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1 | INTRODUCTION
Male lower urinary tract symptoms (LUTS) have conventionally been
considered as merely the result of age-related prostatic enlargement.
However, such a simple explanation is not accepted due to the heter-
ogenous characteristics of LUTS and their relationships with systemic
diseases.1
Numerous studies have demonstrated that benign prostatic
hyperplasia (BPH) may be caused by a chronic inflammatory process
or immune cell infiltration.2-6 In response to prostatic inflammation,
immune cells generate cytokines that affect other cells to produce
growth factors. This enhances the proliferation of stromal and epithe-
lial cells, and this is sustained by an autoimmune mechanism, leading
to an increase in prostate volume.5 Chronic inflammation can cause
tissue damage, potentially resulting in a repetitive process of wound
healing which is associated with BPH.3-6
Recently, the neutrophil-to-lymphocyte ratio (NLR) has been pro-
posed as a surrogate marker for various conditions, including the
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systemic inflammatory response, metabolic syndrome, outcomes in
oncologic fields, cardiovascular disorders, and other medical disor-
ders.7-13 There have also been reports of its significance in urology.
For example, associations have been reported with biochemical failure
in prostate cancer,14 the cancer-specific survival of patients with met-
astatic renal cell carcinoma,15 and the spontaneous passage of ure-
teral stones.16 Ozer et al.3 showed an association of NLR with severe
LUTS and the progression of BPH. Similarly, Tanik et al.2 suggested
NLR was a predictor of BPH progression. However, there are only lim-
ited data on an association between NLR and intravesical prostatic
protrusion (IPP), an anatomical feature caused by the growth of pros-
tatic lateral and median lobes. Considering the role of IPP as a marker
of bladder outlet obstruction (BOO),17-20 we need well-designed stud-
ies to establish how prostatic morphological features (especially the
degree of IPP, as well as the total prostate volume [TPV] and the tran-
sitional zone volume [TZV]) vary according to the NLR. We aimed to
analyze the association between NLR and the degree of IPP. To our
knowledge, this is the first study on this topic.
2 | METHODS
2.1 | Ethics statement
This study was approved by the Institutional Ethics Committee of
Catholic Kwandong University College of Medicine after reviewing
the study protocol and procedures (IS18RISI0076). The requirement
for written consent was waived because of the retrospective nature
of the study. The data were anonymized before the analysis.
2.2 | Study population
Medical records from 250 men aged >50 years who presenting with
LUTS at our outpatient clinic between January 2014 and December
2018 were retrospectively analyzed. We collected data on patient
demographics and clinical characteristics, including age, body mass
index, prostate-specific antigen values, TPV and TZV on transrectal
ultrasound (TRUS), degree of IPP, and neutrophil/lymphocyte counts
from peripheral blood samples. The peripheral blood sampling for NLR
assessment was done just before performing TRUS. The exclusion
criteria included the following: suspected bacterial or viral infection by
laboratory results; malignancy; autoimmune or systemic inflammatory
diseases that may influence NLR values; the use of anti-inflammatory
drugs or 5-alpha reductase inhibitors; immunotherapy; urinary tract
stone; and history of prostatic surgery. Patients with incomplete data
were excluded from the statistical analysis.
2.3 | Measurement of the prostate
TPV, TZV, and IPP were measured using TRUS. TPV was automatically
calculated by multiplying together the largest antero-posterior, trans-
verse, and cephalocaudal diameters, and multiplying this by 0.52.
Measuring TZ was done in a similar manner, as previously pres-
ented.21 Determination of IPP was done after checking the vertical
length between two points; end of the protrusion and base of blad-
der.18 All the measurements were made by a single urologist (MSC).
2.4 | Statistical analysis
To compare continuous and categorical variables, Student's t test
(or Kruskal–Wallis test) and the χ2 test were performed. Pearson's
method was used for the correlation analysis. Multivariate logistic
regression models that included all the collected variables were con-
structed to identify the factors that were predictive of IPP. The cut-
off values were determined using the area under the receiver operat-
ing characteristic (ROC) curve. The statistical analyses were per-
formed with R statistics version 3.5.1. Results were considered
significant at P < 0.05.
3 | RESULTS
Table 1 summarizes the baseline patient characteristics. The median
IPP was 3.3 mm (interquartile range, 0.0–7.4), and 24.4% (61/250) of
TABLE 1 Baseline characteristics of patients (n = 250)
Median (interquartile range)
Age, y 65.0 (57.5–71.0)
BMI, kg/m2 24.1 (22.6–25.6)
PSA, ng/mL 1.8 (0.9–3.4)
Prostate volume on TRUS, cm3
TPV 39.5 (24.0–61.9)
TZV 22.0 (9.7–44.0)
IPP on TRUS, mm 3.3 (0.0–7.4)
WBC, /μL 5880 (5000–6740)
NLR 1.93 (1.42–2.45)
Abbreviations: BMI, body mass index; PSA, prostate-specific antigen;
TRUS, transrectal ultrasound; TPV, total prostate volume; TZV, transitional
zone volume; IPP, intravesical prostatic protrusion; WBC, white blood cell;
NLR, neutrophil-to-lymphocyte ratio.
TABLE 2 Distribution of the NLR according to IPP in the overall
cohort (n = 250)
IPP <10 mm IPP ≥10 mm
(n = 189) (n = 61) P value
Mean (SD)
Age, y 64.0 (9.4) 69 (7.9) 0.019
BMI, kg/m2 24.0 (2.3) 24.7 (2.6) 0.085
PSA, ng/mL 2.5 (2.4) 4.7 (3.8) <0.001
WBC, /μL 5930 (1070) 6028 (1180) 0.574
NLR 1.90 (0.7) 2.60 (1.2) <0.001
Abbreviations: IPP, intravesical prostatic protrusion; SD, standard
deviation; BMI, body mass index; PSA, prostate-specific antigen; TRUS,
transrectal ultrasound; WBC, white blood cell; NLR,
neutrophil-to-lymphocyte ratio.
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the patients had IPP ≥10 mm. In the overall cohort, there was a sig-
nificant difference in NLR according to IPP (P < 0.001, Table 2). Pear-
son correlation analysis revealed a positive correlation between NLR
and IPP (P < 0.001, r = 0.459; Figure 1). The predictors for IPP
≥10 mm are presented in Figure 2. In the multivariate logistic regres-
sion analysis, NLR was found to be an independent predictor of IPP
≥10 mm (odds ratio [OR] 2.95; 95% confidence interval
[CI] 1.59–5.47; P = 0.0006). TZV was not a significant predictor of
IPP (OR 0.97; 95% CI 0.92–1.03; P = 0.341). The area under the
curve obtained from the ROC curve was 0.732 (95% CI:
0.643–0.821). The NLR value with the highest combined sensitivity
and specificity predicting IPP ≥10 mm in our cohort was 2.2 (speci-
ficity: 73.1%, sensitivity: 60.0%; Figure 3).
For further analyses, we used two cut-off values: 40 cm3 for TPV
and 10 mm for IPP (Table 3). Of the 250 patients, 142 had prostate
volumes <40 cm3. In these 142 patients, we compared NLR between
those with IPP < 10 mm (group 1) and those with IPP ≥10 mm (group
2), which revealed a significant difference (1.71 ± 0.57 vs 2.50 ± 0.71;
P < 0.001). Similarly, in patients with larger volumes (≥40 cm3), a sig-
nificant difference in NLR was noted between those with IPP < 10 mm
(group 3) and those with IPP ≥10 mm (group 4) (2.07 ± 0.77 vs 2.50
± 0.80; P < 0.001).
We also compared NLR between the patients with TPV
<40 cm3 and IPP ≥10 mm (n = 22, group 2) and those with TPV
≥40 cm3 and IPP <10 mm (n = 69, group 3), which again revealed a
significant difference (2.50 ± 0.71 vs 2.07 ± 0.77; P = 0.020;
Table 3).
Table 4 shows the result when we compared NLR between the
patients with small (<40 cm3) prostates or prostates with
IPP < 10 mm (n = 211) and those with larger prostates and IPP
≥10 mm (n = 39).
F IGURE 1 Correlation between the neutrophil-to-lymphocyte
ratio (NLR) and intravesical prostatic protrusion (IPP) [Color figure can
be viewed at wileyonlinelibrary.com]
F IGURE 2 Multivariate logistic regression analysis in the
prediction of intravesical prostatic protrusion (IPP) ≥10 mm. *P < 0.05,
***P < 0.001 [Color figure can be viewed at wileyonlinelibrary.com]
F IGURE 3 Receiver operating characteristic (ROC) curve to
predict intravesical prostatic protrusion (IPP) ≥10 mm [Color figure
can be viewed at wileyonlinelibrary.com]
TABLE 3 Distribution of the NLR according to prostate volume and IPP
TPV <40 cm3 TPV ≥40 cm3
IPP <10 mm
(group 1, n = 120)
IPP ≥10 mm
(group 2, n = 22)
IPP <10 mm
(group 3, n = 69)
IPP ≥10 mm
(group 4, n = 39) P value
Mean (SD)
Age, y 62.2 (6.6) 65.7 (5.8) 67.9 (9.4) 68.8 (9.0) <0.001
BMI, kg/m2 24.2 (2.5) 24.1 (2.7) 23.6 (2.2) 24.5 (1.8) 0.779
PSA, ng/mL 1.4 (1.4) . 2.1 (1.0) 4.1(3.4) 5.0 (3.9) <0.001
WBC, /μL 5883 (1189) 6010 (987) 5931 (849) 6132 (1333) 0.769
NLR 1.71 (0.57) 2.50 (0.71) 2.07 (0.77) 2.50 (0.80) <0.001
Abbreviations: TPV, total prostate volume; IPP, intravesical prostatic protrusion; SD, standard deviation; BMI, body mass index; PSA, prostate-specific
antigen; WBC, white blood cell; NLR, neutrophil-to-lymphocyte ratio.
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4 | DISCUSSION
BPH involves the growth of epithelial and stromal cells in the transi-
tion zone and periurethral areas.22 The roles of androgens and growth
factors in the onset and progression of BPH have been established
over the last few decades, and inflammation has also been reported to
play a role. Zlotta et al.23 demonstrated that chronic inflammation was
noted in over 70% of men with BPH in their autopsy study, and there
was an association between the degree of BPH and the level of
chronic inflammation. Factors that may be associated with inflamma-
tion of the prostate involve infection, environmental or hormonal con-
ditions, and systemic inflammation associated with metabolic
syndrome.3,24 Several reports have demonstrated the role of immune
cell infiltration and pro-inflammatory mediators in BPH pathogene-
sis.25,26 For example, Nostrom et al.25 highlighted the involvement of
interleukin-8 and monocyte chemoattractant protein-1.25 Chronic
inflammation causes damage to prostatic tissue and subsequent
repetitive process of wound healing; this tissue remodeling then
results in the overgrowth of prostatic tissue.1,3
NLR, a recognized surrogate marker of the state of inflammation
in the body, is reasonable and can be simply determined from com-
plete blood count by peripheral blood sampling. Its significance has
been well highlighted in various medical fields.7-13 Several reports
have demonstrated good correlations between NLR and severe LUTS
or the progression of BPH.3 Tanik et al.2 reported that NLR was posi-
tively correlated with the International Prostate Symptom Score
(IPSS) and negatively correlated with the maximum urinary flow rate
(Qmax) and the clinical status of patients. NLR showed stronger corre-
lations with these parameters than erythrocyte sedimentation rate
and C-reactive protein. As for a reference value of NLR in the Korean
population, Lee et al.27 investigated a large cohort (6268 men and
5892 women) of Koreans and reported that the mean NLR was 1.62,
1.67, and 1.73 for age groups 50s, 60s, and above 70s, respectively.
IPP results from the growth of prostatic lateral and median lobe.
Several authors have reported that IPP might cause an obstruction of
‘ball valve’ type and malfunction of the funneling action by the bladder
neck.18,28 This protrusion has been reported to be significantly corre-
lated with greater obstructive IPSS, decreased Qmax, and increased
postvoid residual urine volume.17,18,20 Thereafter, numerous studies
have examined IPP and it has been reported to be a valuable anatomi-
cal marker for determining BOO which should be confirmed by
urodynamic study.17 Lim et al.20 reported that IPP was a better pre-
dictor for BOO than was prostate volume, emphasizing that the exis-
tence of BOO is important to the urologists who can offer a more
proactive treatment strategy such as surgery.
For these reasons, we focused in this study on the association
between NLR and IPP. Although several studies2,3 have reported
associations between NLR and TPV (or TZV) or BPH progression,
there was no report showing an association between NLR and IPP.
The IPP threshold for defining BOO is recognized to be 10 mm, as
was highlighted in a systematic review; this reported that IPP > 10 mm
had a similar diagnostic accuracy as uroflowmetry alone.29 We there-
fore used the cut-off value of 10 mm for IPP in the present study.
NLR showed a significant correlation with IPP (Figure 1). In multivari-
ate logistic regression analysis (Figure 2), NLR was found to be an
independent predictor of IPP ≥10 mm. The cut-off value for NLR
predicting IPP ≥10 mm in our cohort was 2.2. A possible explanation
of the correlation between NLR and IPP may be that chronic inflam-
mation and the repetitive wound healing process results in a specific
morphological change, intravesical protrusion of the prostatic
median lobe.
Our analysis of patients with relatively small TPV (<40 cm3)
showed that high NLR was associated with a high likelihood of having
IPP ≥10 mm (group 1 vs group 2, Table 3). This unique group of
patients having a small prostate gland with high IPP (and who would
therefore be expected to be unobstructed according to TPV size
criteria) is important because they experience obstruction during
voiding due to the ‘ball valve’ effect caused by the IPP.20 As seen in
Table 3, the difference in the NLR according to IPP was greater in the
smaller prostate group than in the larger prostate group (1.71 vs 2.50
in group 1 vs 2 and 2.07 vs 2.50 in group 3 vs 4), although both had
statistically significant differences.
We also compared NLR between the patients with small TPV
(<40 cm3) and IPP ≥10 mm (group 2) and those with TPV ≥40 cm3 but
with IPP < 10 mm (group 3). Interestingly, those with a small prostate
and high IPP showed much higher NLR values than those with a larger
prostate but without IPP (2.50 ± 0.71 vs 2.07 ± 0.77; P = 0.020,
Table 3). This finding suggests that NLR is more closely related to the
IPP of the median lobe than to TPV; however, a future study with a
larger number of cases is needed to confirm this.
When we compared NLR between the patients with small
(<40 cm3) prostates or prostates with IPP <10 mm and those with
larger prostates and IPP ≥10 mm, those with a larger prostate and
high IPP showed much higher NLR values than those with a smaller
prostate or a prostate with IPP <10 mm (Table 4). This finding is in
line with a previous report3 which demonstrated that more patients
TABLE 4 Comparison of the NLR between small (<40 cm3)









≥10 mm (n = 39) P value
Mean (SD)
Age, y 64.3 (9.2) 68.8 (9.0) 0.027
BMI, kg/m2 24.1 (2.4) 24.5 (1.8) 0.568
PSA, ng/mL 2.7 (1.9) 5.0 (3.9) <0.001
WBC, /μL 5929 (1073) 6132 (1333) 0.778
NLR 1.99 (0.86) 2.50 (0.80) <0.001
Abbreviations: IPP, intravesical prostatic protrusion; SD, standard
deviation; BMI, body mass index; PSA, prostate-specific antigen; WBC,
white blood cell; NLR, neutrophil-to-lymphocyte ratio.
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underwent surgical treatment when they have higher NLR, com-
pared to those with lower NLR. The authors suggested that the stan-
dard medical therapy for BPH is not sufficient for patients with high
prostatic inflammation. Similarly, Ficarra et al.24 reported that the
use of alpha-blockers (with or without 5-alpha reductase inhibitors)
can be insufficient to reduce LUTS in patients with high-grade
inflammation.
Based on the positive correlations between NLR and severe
symptoms or the progression of BPH, several reports have pro-
posed that anti-inflammatory drugs could be used alongside stan-
dard medical therapy for BPH to prevent disease progression and
relieve symptoms.2,3 The use of traditional non-steroidal anti-
inflammatory drugs (NSAIDs) and cyclooxygenase-2 inhibitors has
been proposed for relieving LUTS/BPH. A recent meta-analysis of
three randomized controlled trials that compared NSAIDs with pla-
cebo demonstrated that such drugs improved LUTS and
uroflowmetric parameters.30 On this point, we agree with a previ-
ous report3 that demonstrated that the predictive value of NLR for
treatment of BPH/LUTS may be more significant, although there
has been no study yet analyzing the response to anti-inflammatory
drugs according to the serum NLR of the patient. The present
study revealed a positive correlation between NLR and IPP. We
think these findings provide additional data for future study to elu-
cidate whether NLR can be used to determine who may benefit
most from the anti-inflammatory medication.
Although our study revealed a novel finding, the retrospective
nature and relatively small number of patients of this investigation is
the main limitation. Second, we were unable to clearly investigate the
pathogenesis of the formation of IPP in patients with high NLR.
Clearly, inflammation is not the only factor to cause IPP, and it is likely
that various factors are associated with this morphological change. In
particular, in men with normal NLR but high IPP, the IPP may have
other causes than inflammation. On this issue, further studies of men
with IPP at initial presentation are needed to determine whether the
progression of IPP over time differs according to NLR. Nevertheless,
we believe the present study provides adequate preliminary data with
respect to the association between NLR and IPP. Finally, generaliza-
tion of this study's results should be drawn with prudence, because all
patients we studied were selected from a single institution in Korea.
In conclusion, our analysis demonstrated that NLR can be used as a
surrogate marker for presence of a specific morphological change, IPP. The
clinical value of NLR would be especially important in men with a small
prostate gland but high IPP. The NLR was more strongly correlated with
IPP than with TPV. Further studies are needed to confirm our findings.
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